Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

106 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A single dose of 6 or 12 mg of pegfilgrastim for peripheral blood progenitor cell mobilization results in similar yields of CD34+ progenitors in patients with multiple myeloma.
Bruns I, Steidl U, Kronenwett R, Fenk R, Graef T, Rohr UP, Neumann F, Fischer J, Scheid C, Hübel K, Haas R, Kobbe G. Bruns I, et al. Among authors: kronenwett r. Transfusion. 2006 Feb;46(2):180-5. doi: 10.1111/j.1537-2995.2006.00699.x. Transfusion. 2006. PMID: 16441592 Clinical Trial.
Pegylated granulocyte colony-stimulating factor mobilizes CD34+ cells with different stem and progenitor subsets and distinct functional properties in comparison with unconjugated granulocyte colony-stimulating factor.
Bruns I, Steidl U, Fischer JC, Czibere A, Kobbe G, Raschke S, Singh R, Fenk R, Rosskopf M, Pechtel S, von Haeseler A, Wernet P, Tenen DG, Haas R, Kronenwett R. Bruns I, et al. Among authors: kronenwett r. Haematologica. 2008 Mar;93(3):347-55. doi: 10.3324/haematol.12081. Epub 2008 Feb 11. Haematologica. 2008. PMID: 18268278 Free article.
The level of minimal residual disease in the bone marrow of patients with multiple myeloma before high-dose therapy and autologous blood stem cell transplantation is an independent predictive parameter.
Korthals M, Sehnke N, Kronenwett R, Bruns I, Mau J, Zohren F, Haas R, Kobbe G, Fenk R. Korthals M, et al. Among authors: kronenwett r. Biol Blood Marrow Transplant. 2012 Mar;18(3):423-431.e3. doi: 10.1016/j.bbmt.2011.07.002. Epub 2011 Jul 13. Biol Blood Marrow Transplant. 2012. PMID: 21745451 Free article.
Gene expression profiling identifies significant differences between the molecular phenotypes of bone marrow-derived and circulating human CD34+ hematopoietic stem cells.
Steidl U, Kronenwett R, Rohr UP, Fenk R, Kliszewski S, Maercker C, Neubert P, Aivado M, Koch J, Modlich O, Bojar H, Gattermann N, Haas R. Steidl U, et al. Among authors: kronenwett r. Blood. 2002 Mar 15;99(6):2037-44. doi: 10.1182/blood.v99.6.2037. Blood. 2002. PMID: 11877277 Free article.
Reliable engraftment, low toxicity, and durable remissions following allogeneic blood stem cell transplantation with minimal conditioning.
Kobbe G, Schneider P, Aivado M, Zohren F, Schubert D, Fenk R, Neumann F, Kronenwett R, Pape H, Rong A, Royer-Pokora B, Hildebrandt B, Germing U, Gattermann N, Heyll A, Haas R. Kobbe G, et al. Among authors: kronenwett r. Exp Hematol. 2002 Nov;30(11):1346-53. doi: 10.1016/s0301-472x(02)00923-2. Exp Hematol. 2002. PMID: 12423689 Free article.
106 results